Modality
mAb
MOA
PRMT5i
Target
KRASG12C
Pathway
Complement
Angelman
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
Jun 2017
→ Nov 2025
Phase 1Current
NCT03817154
1,693 pts·Angelman
2017-06→2025-11·Recruiting
1,693 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-285mo agoFast Track· Angelman
2025-11-015mo agoInterim· Angelman
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1
Recruit…
Catalysts
Fast Track
2025-10-28 · 5mo ago
Angelman
Interim
2025-11-01 · 5mo ago
Angelman
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03817154 | Phase 1 | Angelman | Recruiting | 1693 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |